Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.64 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11393853 | 0.91 | DRD2 (0.59) | DRD2HTR2CDRD3 | |
| SCHEMBL6926283 | 0.91 | DRD2 (0.72) | DRD2HTR2CDRD3GRM2CHRM2 | |
| Hydrochloric Acid SCHEMBL11397089 | 0.90 | DRD2 (0.58) | DRD2HTR2CDRD3 | |
| SCHEMBL13063397 | 0.87 | DRD2 (0.58) | DRD2HTR2CDRD3GRM2CHRM2 | |
| SCHEMBL16217327 | 0.86 | DRD2 (0.49) | DRD2HTR2CDRD3HTR1AHTR2B | |
| SCHEMBL31060813 | 0.83 | DRD2 (0.87) | DRD2DRD3HTR1ADRD4 | |
| SCHEMBL12524340 | 0.82 | DRD2 (0.73) | DRD2HTR2CDRD3GRM2CHRM2 | |
| SCHEMBL10079117 | 0.81 | HTR2C (0.50) | DRD2HTR2CGRM2DRD4 | |
| SCHEMBL16660422 | 0.81 | HTR2C (0.50) | DRD2HTR2CGRM2DRD4 | |
| SCHEMBL22415904 | 0.80 | DRD2 (0.65) | DRD2HTR2CDRD3GRM2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946266-B2 | Substituted triazole and imidazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946266-B2 | Substituted triazole and imidazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8877745-B2 | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| EP-2508526-A1 | Spiroalkene carboxamide derivatives and their use as chemokine receptor modulators | Ares Trading SA (CH) | 2012-10-10 | — | — | EP | disclosed |
| WO-2012130915-A1 | SPIROALKENE CARBOXAMIDE DERIVATIVES AND THEIR USE AS CHEMOKINE RECEPTOR MODULATORS | ARES TRADING S.A. (CH) | 2012-10-04 | — | — | WO | disclosed |
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| US-20100076024-A1 | Novel Compounds as Serine Protease Inhibitors | ZIMMERMANN KASPAR | 2010-03-25 | — | — | US | disclosed |
| US-20100076024-A1 | Novel Compounds as Serine Protease Inhibitors | ZIMMERMANN KASPAR | 2010-03-25 | — | — | US | disclosed |
| WO-2008101953-A1 | COMPOUNDS OF FORMULA (I) AS SERINE PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076024-A1 | Novel Compounds as Serine Protease Inhibitors | PRSS1, SERPINB1, SPINT2 | DRD2 4641/4885HTR2C 3007/4885DRD3 4316/4885 |
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | DRD2 3001/4885HTR2C 549/4885DRD3 2048/4885 |
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | CCR2, CXCR2, CYSLTR2 | DRD2 491/4885HTR2C 226/4885DRD3 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.